Glenmark Pharmaceuticals GLENMARK
Branded formulations (India derma/respiratory, Europe, emerging markets), US generics and the Ichnos Glenmark Innovation (IGI) biotech arm
Mapped in 1 theme: Pharmaceuticals.
Where Glenmark Pharmaceuticals sits in the supply chain
Glenmark Pharmaceuticals appears in 2 supply-chain layers in one theme, Pharmaceuticals.
Pharmaceuticals › Specialty & innovation (R&D)
OwnerOther companies in this layer
Pharmaceuticals › Generics (US & export)
Direct supplierOther companies in this layer
Revenue and profit
| ₹ Cr | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | 11,813 | 13,322 | 16,983 |
| Net profit | −1,434 | 1,047 | 1,362 |
Latest-year revenue ₹16,983 Cr (FY26, company-wide). Wider screens show FY22 onwards.
Strengths
- IGI licensed trispecific antibody ISB 2001 to AbbVie for US$700m upfront plus up to US$1.225bn milestones and royalties (Sep 2025) - the biggest Indian out-licensing deal
- Ryaltris (nasal spray) is a growing global specialty brand
- Debt reduced after selling Glenmark Life Sciences (API) to Nirma
Risks
- FY26 profit is inflated by the one-off AbbVie upfront - FY27 comparisons will be tough
- Repeated USFDA compliance setbacks at several plants have held back US launches
- Innovation spend remains high relative to the base business
Common questions
What does Glenmark Pharmaceuticals do?
Branded formulations (India derma/respiratory, Europe, emerging markets), US generics and the Ichnos Glenmark Innovation (IGI) biotech arm.
Where does Glenmark Pharmaceuticals sit in the supply chain?
Glenmark Pharmaceuticals (NSE: GLENMARK) is mapped in 2 supply-chain layers: Specialty & innovation (R&D) (Pharmaceuticals) and Generics (US & export) (Pharmaceuticals).
Who are Glenmark Pharmaceuticals' peers?
In the Specialty & innovation (R&D) layer of Pharmaceuticals: Sun Pharmaceutical Industries, Wockhardt, Zydus Lifesciences, Lupin and SPARC (Sun Pharma Advanced Research Company).
What is Glenmark Pharmaceuticals' market cap and valuation?
As of 30 Oct 2026: market cap ₹65,042 Cr, P/E 20.8x, ROCE 39.8%, ROE 23.6%, dividend yield 0.22%.